USE OF NIMESULID IN RHEUMATOLOGY


Cite item

Full Text

Abstract

The article is dedicated to the characteristics of Nimesulide (Nise) in comparison with other nonsteroidal anti-inflammatory drugs (NSAIDs). It was found that Nimesulide belongs to the partially selective NSAIDs, which are characterized by the preferential inhibition of COX-2. The mechanisms of action of Nimesulide in rheumatic diseases, in particular in osteoarthrosis are discussed. The data for its high clinical efficacy and safety are presented. It is emphasized that Nimesulide is an effective drug for the treatment of diseases of the joints and spine due to rapid and pronounced analgesic and anti-inflammatory actions without chondrotoxic properties, and the frequency of side effects is comparable to the most popular NSAIDs.

References

  1. Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclooxigenase-2 inhibitors. Arthritis Rheum 2000;43:4-13.
  2. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
  3. Practice Guidelines and Recommendations from AHRQ. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis: Executive Summary From AHRQ. Agency for Healthcare Quality and Research (AHRQ). AHRQ. 2006;8(2).
  4. Rainsford K. Nimesulide - a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006;22 (6):1161-70.
  5. Rainsford K. Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide. Inflammopharmacology 2006;14(3-4):120-37.
  6. Якимова С.С. Поражение пищеварительной системы нестероидными противовоспалительными препаратами // Consilium medicum. Т. 12. № 2. С. 5-11.
  7. Kullich WC, Niksic F, Clein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: A pilot clinical study. IJCP 2002;(Suppl. 128):24-29.
  8. Saito S, Katoh M, Masumoto M, et al. Involvement of MMP-1 and MMP-3 in collagen degradation induced by IL-1 in rabbit cartilage explant culture. Life Sci 1998;62:359-65.
  9. Wu J.J, Lark M.W, Chun L.E, et al. Sites of stromelysin cleavage in collagen types II, IX, and XI of cartilage. J Biol Chem 1991;266:5625-28.
  10. Clark AG, Jordan JM, Vilim V, et al. Serum cartilage oligomeric matrix protein reflects 28 IJCP Supplement 128 July 2002 osteoarthritis presence and severity. Arthritis Rheum 1999;42(11):2356-64.
  11. Vilim V, Vytasck R, Vencovsky J, et al. The effect of synovitis on COMP levels in sera of patients with osteoarthrosis (abstract). Trans Orthop Res Soc 1999;24:441.
  12. Bennett A. Nimesulide: a well-established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: Vane J J, Botting RM eds. Therapeutic Roles of Selective COX-2 Inhibitors. London: William Harvey Press, 2001:524-40.
  13. Rainsford KD. The discovery, development and novel actions of nimesulide. In: Rainsford KD, ed. Nimesulide, Actions and Uses. Basel, Boston, Berlin: Birkhauser Verlag, 2005.
  14. Zheng SX, Monithys-Mickalad A, et al. In vitro study of the antioxidant properties of nimesulide and 4-OH nimesulide: effects on HRP- and luminal dependent chemoluminescence produced by human chondrocytes. Osteoarthri Cartilage 2000;8:419-25.
  15. Kidd PM. Glutathione; systemic protectant against oxidative and free radical damage. Alt Med Rev 1997;2:155-76.
  16. Kulich W, Fagerer N, Schwann H. Effect of the NSAID nimesulide on the radical scavenger glutathione S-transferase in patients with osteoarthritis of the knee. Curr Med Res Opin 2007,23,8:1981-86.
  17. Parr D, Darekar B, Fletcher A, et al. Joint pain and quality of life: results of a randomized trial. Br J Clin Pharmacol 1989; 27: 235-42.
  18. Beaulieu A, Peloso P, Haraoui B, et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis:a randomized controlled trial. Pain Res Manag 2008;13(2):103-10.
  19. Kriegel W, Korff K, Ehrlich J, et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract. 2001;55(8): 510-14.
  20. Pohjolainen T, Jekunen A, Autio L, et al. Treatment of acute LBP with COX-2 selective inh1 NSAID nimesulide. Spine 2000;25(12):1579-85.
  21. Tannenbaum H, Bombardier C, Davis P, et al. An evidence-based approach to prescribing nonsteroidal anti-iflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57.
  22. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
  23. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.
  24. De Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001;1:1.
  25. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-16.
  26. Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract 2004;144(Suppl.):27-32.
  27. Conforti A, Leone R, Moretti U, et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001;24:1081-90.
  28. Laporte J, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004;27:411-20.
  29. Каратеев А.Е., Алексеева Л.И., Братыгина Е.А. и др. Оценка частоты развития побочных эффектов при длительном использовании нимесулида в реальной клинической практике // РМЖ. 2009. № 21. С. 1-6.
  30. Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003;327:18-22.
  31. Boelsterli U. Nimesulide and hepatic adverse affects: roles of reactive metabolites and host factors. Int J Clin Pract 2002;(Suppl.128):30-36.
  32. Boelsterli U. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002;25:633-48.
  33. Каратеев А.Е., Насонова В.А. НПВП-ассоциированная гепатопатия: проблема нимесулида // Научно-практическая ревматология. 2004. № 1. С. 34-37.
  34. Press release. European Medicines Agency recommends restricted use of nimesulid-containing medicinal products. Doc. Ref. EMEA/432604/2007 На сайте: http://www.emea.europa.eu.
  35. Helin-Salmivaara A, Virtanen A, Veslainen R, et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart 2006;27:1657-63.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies